胃癌及食管胃结合部癌免疫及靶向治疗研究进展  

Research progress in immunotherapy and targeted therapy for gastric cancer and esophagogastric junction cancer

作　　者：伍杨 李甜[2] 张润兵 史婷婷 高春 郑晓凤[3] 张久聪 Wu Yang;Li Tian;Zhang Runbing;Shi Tingting;Gao Chun;Zheng Xiaofeng;Zhang Jiucong(Department of Gastroenterology,940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army,Lanzhou 730050,China;First School of Clinical Medical of Gansu University of Traditional Chinese Medicine,Lanzhou 730000,China;Department of Gastroenterology,Second Clinical Medical School of Lanzhou University,Lanzhou 730030,China)

机构地区：[1]中国人民解放军联勤保障部队第九四〇医院消化内科,兰州730050 [2]甘肃中医药大学第一临床医学院,兰州730000 [3]兰州大学第二临床医学院消化科,兰州730030

出　　处：《国际肿瘤学杂志》2024年第9期595-600,共6页Journal of International Oncology

基　　金：甘肃省青年科技基金(22JR5RA1012、23JRRA1673);兰州市科技计划项目(2023-2-29)。

摘　　要：胃癌及食管胃结合部癌(EGJC)是最常见的恶性肿瘤之一,传统治疗方法通常以放化疗及手术治疗为主,但对患者的预后改善有限。近年来随着治疗手段的发展,免疫治疗和靶向治疗逐渐被公认为一线治疗方法。免疫治疗中,纳武利尤单抗和帕博利珠单抗对程序性死亡受体配体1阳性的患者表现出明确疗效,而其他免疫治疗(如肿瘤疫苗、工程化T细胞和非特异性免疫调节剂等)目前仍在试验或研发中。此外,靶向治疗目前仅在某些特定人群或在二线治疗中表现出较大的治疗潜力,如曲妥珠单抗对人表皮生长因子受体2阳性的患者具有明确疗效,而对其他分子靶点扩增的患者疗效欠佳。深入探讨免疫治疗及靶向治疗在胃癌及EGJC中的研究进展,将有助于改善患者预后,并为肿瘤的精准治疗提供参考。Gastric cancer and esophagogastric junction cancer(EGJC)are one of the world's most common types of malignant tumors.Traditional treatment methods mainly include radiotherapy,chemotherapy,and surgery,but the patients'prognosis is limited.In recent years,with the development in treatment methods,immunotherapy and targeted therapy are gradually recognized as the first-line treatment methods.In immunotherapy,nivolumab and pabolizumab have shown clear efficacy in patients with programmed deathligand 1 positive,while other immunotherapies(such as tumor vaccine,engineered T cells,and non-specific immunomodulators)are still being tested or developed.In addition,targeted therapy has only shown comparatively large therapeutic potential in certain specific populations or in second-line treatment.For instance,tratuzumab has a clear curative effect on patients with positive human epidermal growth factor receptor 2,but has suboptimal efficacy in patients with amplification of other molecular targets.An in-depth discussion of the research progress of immunotherapy and targeted therapy in gastric cancer and EGJC will help to improve the prognosis of patients and provide a reference for accurate treatment of tumors.

关 键 词：胃肿瘤 食管胃接合处 免疫疗法 分子靶向治疗 

分 类 号：R735[医药卫生—肿瘤]